--- title: "QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect" type: "News" locale: "en" url: "https://longbridge.com/en/news/285022537.md" description: "QuidelOrtho (QDEL) is set to report earnings tomorrow after market hours. Last quarter, the company exceeded revenue expectations with $723.6 million, a 2.2% year-on-year increase, but missed full-year EPS guidance. Analysts expect a 3.5% revenue decline this quarter. Despite a 21.7% drop in share price recently, analysts maintain a positive outlook, with an average price target of $27 compared to the current price of $12.43. The healthcare equipment sector has seen positive sentiment, with peers like GE HealthCare and Intuitive Surgical reporting strong results." datetime: "2026-05-04T03:14:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285022537.md) - [en](https://longbridge.com/en/news/285022537.md) - [zh-HK](https://longbridge.com/zh-HK/news/285022537.md) --- # QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect Healthcare diagnostics company QuidelOrtho will be reporting earnings this Tuesday after market hours. Here’s what you need to know. QuidelOrtho beat analysts’ revenue expectations last quarter, reporting revenues of $723.6 million, up 2.2% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ revenue estimates but a significant miss of analysts’ full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting QuidelOrtho’s revenue to decline 3.5% year on year, in line with the 2.6% decrease it recorded in the same quarter last year. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has a history of exceeding Wall Street’s expectations. Looking at QuidelOrtho’s peers in the healthcare equipment and supplies segment, some have already reported their Q1 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 7.4%, beating analysts’ expectations by 2.1%, and Intuitive Surgical reported revenues up 23%, topping estimates by 5.8%. GE HealthCare traded down 11.2% following the results while Intuitive Surgical was up 7.2%. Read our full analysis of GE HealthCare’s results here and Intuitive Surgical’s results here. There has been positive sentiment among investors in the healthcare equipment and supplies segment, with share prices up 6% on average over the last month. QuidelOrtho is down 21.7% during the same time and is heading into earnings with an average analyst price target of $27 (compared to the current share price of $12.43). **WHILE YOU’RE HERE: The Next Palantir?** One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it. This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. **Claim The Stock Ticker for Free HERE**. ### Related Stocks - [QDEL.US](https://longbridge.com/en/quote/QDEL.US.md) - [GEHC.US](https://longbridge.com/en/quote/GEHC.US.md) - [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md) - [ISUL.US](https://longbridge.com/en/quote/ISUL.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md) ## Related News & Research - [QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences | QDEL Stock News](https://longbridge.com/en/news/287052428.md) - [Harvest Portfolios Group Inc. Sells 11,094 Shares of Intuitive Surgical, Inc. $ISRG](https://longbridge.com/en/news/287027126.md) - [Resona Asset Management Co. Ltd. Reduces Stock Holdings in Intuitive Surgical, Inc. $ISRG](https://longbridge.com/en/news/286897112.md) - [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md) - [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)